MIRA Pharmaceuticals, Inc. (MIRA )

Currency in USD Disclaimer
$1.25 +$0.25 (25%)
Closed 03/13/2025
$0.96
$1.33
$0.51
$5.01

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol MIRA
  • Company MIRA Pharmaceuticals, Inc.
  • Price $1.25
  • Changes Percentage 25
  • Change 0.25
  • Day Low $0.96
  • Day High $1.33
  • Year High $5.01
  • Year Low $0.51
  • Market Cap $20,701,065
  • Price Avg 50 EMA (D) $1.14
  • Price Avg 200 EMA (D) $1.29
  • Exchange NASDAQ
  • Volume 2,484,835
  • Average Volume 343,615
  • Open $1
  • Previous Close $1
  • EPS -0.55
  • PE -2.27
  • Earnings Announcement 2025-05-28 12:00:00
  • Shares Outstanding $16,560,852

Company brief: MIRA PHARMACEUTICALS, INC. (MIRA )

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

MIRA Corporation News

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

March 13, 2025 at 12:00 pm ET

accessnewswire.com -- MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric d...

Income Statement